The phrase "the 34 symptoms of perimenopause" is one of the most-searched menopause queries online. Yet it does not appear in any major medical guideline. It is a popular framework that grew out of patient advocacy literature in the early 2000s and now circulates widely on social media. The list is useful because it names experiences you may have dismissed as unrelated, but it is not a diagnostic checklist. What follows maps each commonly cited symptom to its underlying hormonal mechanism. It cites the best available prevalence data from the Study of Women's Health Across the Nation (SWAN) and other cohorts. And it flags which symptoms you can track at home and which warrant clinical attention.
Free interactive tool
Perimenopause symptom checklist
Tick your symptoms and see them sorted by the hormone this article links them to, with a summary for your appointment.
At a glance
- Perimenopause is a shifting set of symptoms, not a fixed list of 34. A study published in Scientific Reports in January 2025 analyzed 147,501 symptom logs from 4,789 people and found a median of 23 distinct symptoms during perimenopause, against 17 before the transition and 19 after it.
- SWAN data indicate that about 85% of women report at least one menopause transition symptom, most commonly vasomotor symptoms, low mood or sleep disruption.
- Up to 80% of women experience hot flashes during the menopausal transition, and SWAN reports any vasomotor symptoms in roughly 43% of perimenopausal participants.
- Writing in Climacteric in 2024, Wright and colleagues named this cluster the musculoskeletal syndrome of menopause: more than 70% of women experience musculoskeletal symptoms during the transition, and 25% are disabled by them.
- A survey of 17,494 women in 158 countries, published in the journal Menopause in January 2026, found that women aged 35 and over reported fatigue at 83%, exhaustion at 83% and irritability at 80%, even though hot flashes are the symptom most people associate with perimenopause.
In this article
- The 34 symptoms in one list
- About the "34 symptoms" framework: what it is, what it isn't
- Symptoms driven by estrogen decline and fluctuation
- Symptoms driven by low or erratic progesterone
- Symptoms driven by cortisol and HPA-axis change
- Symptoms driven by thyroid and metabolic shifts
- Less-discussed symptoms that catch women off-guard
- The full 34-symptom inventory: mechanism, prevalence, and trackability
- When to escalate: red-flag symptoms requiring urgent care
- What functional medicine practitioners look for
- When to consider booking a consult
- Frequently asked questions
The 34 symptoms in one list
These are the 34 symptoms of perimenopause most often named in the popular list, grouped by the hormonal driver this article maps each one to. The list is a patient education construct rather than a medical classification, so use it to recognize a pattern, not to diagnose yourself.
Driven mainly by estrogen decline and fluctuation
- Hot flashes
- Night sweats
- Mood swings
- Depressive symptoms
- Brain fog / memory lapses
- Difficulty concentrating
- Low libido
- Vaginal dryness
- Painful intercourse
- Recurrent UTIs / urinary urgency
- Bladder leakage
- Joint pain (arthralgia)
- Muscle aches / loss of muscle mass
- Palpitations
- Dizziness / lightheadedness
- Formication
Driven mainly by low or erratic progesterone
- Irregular periods
- Heavier periods
- Insomnia / fragmented sleep
- Anxiety
- Irritability
- Breast tenderness
- Headaches / migraines
Driven mainly by cortisol and HPA axis change
- Fatigue
- Weight gain (central)
- Blood sugar swings
Driven mainly by thyroid and metabolic shifts
- Hair thinning / shedding
Other symptoms carried in the list
- Frozen shoulder
- Tinnitus
- Brittle nails
- Dry skin / itchy skin
- Electric-shock sensations
- Burning mouth / gum issues
- Dry eyes
The full 34 symptom inventory further down this page repeats every one of these names with its mechanism, its estimated perimenopause prevalence and whether you can track it at home.
Interactive tool
Perimenopause symptom checklist
Tick your symptoms and see them sorted by the hormone this article links them to, with a summary for your appointment.
About the "34 symptoms" framework: what it is, what it isn't
The 34 symptoms of perimenopause list came from patient education materials in the early 2000s, and it is not a medical classification. Those materials compiled the most frequently reported complaints during the menopausal transition into a single tally. The framework is not endorsed by The Menopause Society (formerly NAMS) or the Endocrine Society. Neither classifies perimenopausal experiences into a fixed numerical list. Both organizations describe the menopausal transition through the Stages of Reproductive Aging Workshop (STRAW+10) staging system, and group symptoms by physiological domain (vasomotor, genitourinary, sleep, mood, cognition, musculoskeletal).
That said, the framework has clinical value as an awareness tool. SWAN data indicate that approximately 85% of women report at least one menopause-transition symptom, most commonly vasomotor symptoms, low mood, or sleep disruption. Many women experience clusters of complaints (joint pain, palpitations, formication, tinnitus) that they do not connect to declining ovarian function until they see them grouped together. Mapping each symptom to a hormonal mechanism turns a popular list into a teaching tool. It also helps you and your clinician separate normal-transition symptoms from those that need further workup.
Real tracking data give a sharper answer than the number 34. A study published in Scientific Reports in January 2025 analyzed 147,501 symptom logs from 4,789 people. The median number of distinct symptoms logged was 23 during perimenopause. That compares with 17 before the transition and 19 after it. So the typical perimenopausal experience is a shifting set of roughly two dozen symptoms, not a fixed list of 34.
The same study found that logging hot flashes predicted nothing else, apart from night sweats. Hot flashes are the symptom most associated with this stage, but they do not tell you which other symptoms you will get. That is why counting symptoms matters less than mapping each one to a mechanism, which is what the rest of this article does.
There is also a gap between the symptoms women recognize and the symptoms they actually live with. A survey run through a period-tracking app was published in the journal Menopause in January 2026. It covered 17,494 women in 158 countries. Asked which symptoms belong to perimenopause, 71% named hot flashes, 68% named sleep problems and 65% named weight change. Asked what they were actually experiencing, women aged 35 and over reported fatigue at 83%, exhaustion at 83% and irritability at 80%. Depressive mood came in at 77%, sleep problems at 76%, digestive symptoms at 76% and anxiety at 75%. The symptoms that dominate the experience are not the ones most people associate with it.
Two caveats apply throughout this article. First, prevalence figures vary considerably across cohorts because of differences in symptom definitions, recall windows, race/ethnicity composition, and menopausal staging. Second, the mechanisms described are best-supported models, not settled science. Perimenopausal physiology is an area of active investigation, particularly for symptoms like formication, electric-shock sensations, and tinnitus, where the data are sparse.
Symptoms driven by estrogen decline and fluctuation
Estrogen does not simply fall during perimenopause. It fluctuates erratically, sometimes reaching levels higher than premenopausal averages before declining over years. Most of the canonical "34 symptoms" trace to this volatility, because estrogen receptors are distributed throughout the brain, vasculature, bone, skin, urogenital tract, and joints.
Hot flashes and night sweats (vasomotor symptoms)
Up to 80% of women experience hot flashes during the transition. SWAN reports any-VMS in roughly 43% of perimenopausal and 46% of postmenopausal participants. The dominant mechanism is hypothalamic. Declining estrogen causes hypertrophy of KNDy neurons (kisspeptin / neurokinin B / dynorphin) in the infundibular nucleus, which projects to the preoptic thermoregulatory center. Excess neurokinin B signaling at the NK3 receptor triggers inappropriate heat-loss responses: skin vasodilation, sweating, and the hot flash you feel. That receptor is now a drug target. The FDA approved fezolinetant, an NK3 antagonist, in 2023. It approved elinzanetant, sold as Lynkuet, on October 24, 2025. Elinzanetant is a once-daily NK1 and NK3 antagonist. In the OASIS 1 and 2 trials it reduced hot flash frequency by 3.2 per day at 12 weeks. OASIS 3 showed that effect held at 52 weeks. Somnolence is a labeled caution. Whether a non-hormonal option fits your situation is a conversation for your own clinician.
Vaginal dryness, dyspareunia, recurrent urinary tract infections (genitourinary syndrome of menopause, or GSM)
Estrogen maintains epithelial thickness, mucin secretion, and the vaginal microbiome. Withdrawal thins the urogenital epithelium and shifts vaginal pH upward. That predisposes you to friction injury, recurrent infections, and urinary urgency. GSM affects an estimated 27% to 84% of postmenopausal women, with prevalence rising over time. In 2025 the American Urological Association, SUFU and AUGS issued a joint guideline on the genitourinary syndrome of menopause. The Menopause Society has endorsed it. It recommends local low-dose vaginal estrogen, including as a way to reduce recurrent urinary tract infections. It found no evidence linking local vaginal estrogen to breast cancer. It also recommends against laser and radiofrequency devices for this purpose. What is right for you is a decision to make with your own clinician.
Joint pain (arthralgia) in perimenopause
Estrogen modulates cartilage homeostasis and synovial inflammation. Falling levels are associated with increased interleukin-6 signaling and reduced collagen synthesis. SWAN reports joint or muscle pain in roughly 50% to 60% of midlife women, with peaks during late perimenopause. In 2024, writing in Climacteric, Wright and colleagues gave this cluster a name: the musculoskeletal syndrome of menopause. They report that more than 70% of women experience musculoskeletal symptoms during the transition. They also report that 25% are disabled by them. Naming the syndrome matters, because joint pain is often treated as unrelated to your hormonal stage.
Palpitations in perimenopause
Estrogen affects autonomic tone and beta-adrenergic responsiveness. Perimenopausal palpitations are usually benign and self-limited but should always be evaluated to exclude arrhythmia or thyroid disease. A 2026 study in the Journal of Mid-life Health assessed 200 perimenopausal women aged 40 to 50. It found palpitations in 35.5% of them. Those palpitations did not correlate with the autonomic function tests the researchers ran. The study is small, so read the figure as indicative rather than settled. The same study did link vasomotor symptoms to reduced parasympathetic activity.
Formication (sensation of insects crawling on skin)
Less common, but reported in roughly 20% of women across some surveys. The prevailing mechanism is altered cutaneous nerve signaling and dermal collagen loss secondary to estrogen withdrawal.
Brain fog, word-finding difficulty, slowed processing
Estrogen supports synaptic plasticity in the hippocampus and prefrontal cortex. SWAN cognition data document measurable decrements in verbal memory and processing speed during the transition. For most women there is partial recovery post-menopause.
Low libido, mood lability, depressive symptoms
Estrogen interacts with serotonergic and dopaminergic systems. A 2024 meta-analysis in the Journal of Affective Disorders pooled 17 prospective cohorts covering 16,061 women. It found an odds ratio of 1.40 for depressive symptoms in perimenopause compared with premenopause. The same analysis found no increased risk after menopause. Your risk is higher if you have had depression before.
Symptoms driven by low or erratic progesterone
Progesterone declines earlier and more steadily than estrogen during perimenopause, because anovulatory cycles become more frequent. Without ovulation, the corpus luteum does not form, and progesterone production drops. Progesterone is the main endogenous ligand at GABA-A receptors via its allopregnanolone metabolite. So the loss of progesterone disproportionately affects your sleep, anxiety, and irritability.
Insomnia and fragmented sleep
Reported by 40% to 60% of perimenopausal women in SWAN sleep substudies. The mechanism is dual: reduced allopregnanolone-mediated GABAergic tone, and nocturnal vasomotor symptoms disrupting sleep architecture. Many women report difficulty staying asleep rather than falling asleep, a pattern consistent with neurosteroid withdrawal.
Anxiety, panic episodes, irritability
Declining progesterone reduces GABAergic inhibition, leaving your central nervous system in a relatively excitatory state. New-onset anxiety in midlife is one of the more under-recognized presentations of perimenopause.
Heavier or irregular periods
Anovulatory cycles expose the endometrium to unopposed estrogen, so it thickens and sheds unpredictably. Heavy menstrual bleeding (changing protection more than every two hours, passing large clots) warrants clinical evaluation to exclude fibroids, polyps, or endometrial hyperplasia.
Breast tenderness in perimenopause
Estrogen dominance relative to progesterone increases ductal proliferation and water retention in breast tissue.
Menstrual migraines and headaches
Migraines often worsen in perimenopause because of the larger swings in estrogen across the cycle. Progesterone withdrawal in the luteal phase is also a known trigger.
Symptoms driven by cortisol and HPA-axis change
Sleep loss, vasomotor symptoms, and the chronic stress of accumulated midlife demands shift the hypothalamic-pituitary-adrenal (HPA) axis. Estrogen also modulates cortisol-binding globulin and feedback sensitivity at the hypothalamus. So when estrogen declines, your cortisol rhythm often flattens or becomes inverted.
Persistent fatigue and "tired but wired"
A flattened diurnal cortisol curve is associated with both daytime fatigue and difficulty winding down at night.
Central weight gain and waist-circumference increase
SWAN body-composition data document an average visceral-fat increase of roughly 44% across the transition, independent of total weight change. Mechanisms include estrogen-loss-driven shifts in lipolysis preference, sleep-related ghrelin/leptin dysregulation, and cortisol-mediated central adiposity.
Blood sugar swings and increased insulin resistance
Estrogen supports insulin sensitivity. Its decline, combined with cortisol-driven gluconeogenesis, raises your risk of post-meal glucose excursions and reactive hypoglycemia symptoms (shakiness, hunger, irritability).
Sleep architecture change in perimenopause
Beyond simple insomnia, perimenopausal sleep shows reduced slow-wave (deep) sleep and more arousals, which compounds fatigue and cognitive complaints.
Symptoms driven by thyroid and metabolic shifts
Thyroid dysfunction prevalence rises in midlife independently of perimenopause, but the symptom overlap is significant. Endocrine Society guidance emphasizes that hypothyroidism, autoimmune thyroiditis, and subclinical hypothyroidism share many features with perimenopause. They should be excluded when your symptoms are atypical or severe.
Cold intolerance and hypothyroidism
More suggestive of hypothyroidism than perimenopause, though it can occur with vasomotor instability.
Hair thinning, eyebrow loss, dry hair
Estrogen prolongs the anagen (growth) phase of hair follicles. Declining estrogen and androgens, combined with a possible thyroid contribution, can cause diffuse thinning along your part line. Loss of the lateral third of the eyebrow is a classic hypothyroid sign.
Weight gain disproportionate to intake
Both perimenopause and hypothyroidism can present this way. That is why a thyroid panel including TSH, free T4, and free T3 is part of any reasonable workup when fatigue, weight gain, or cold intolerance dominate your picture.
Brain fog overlap with hypothyroidism
Hypothyroidism produces the same cognitive complaints as estrogen withdrawal. That is a key reason thyroid testing is standard before attributing symptoms to perimenopause alone.
Less-discussed symptoms that catch women off-guard
Several symptoms in the "34" list are poorly publicized yet common enough to surprise patients and clinicians alike.
Tinnitus in perimenopause
Ringing or buzzing in the ears is reported more often by perimenopausal women, possibly reflecting estrogen's role in cochlear blood flow and auditory neural function. The data are limited and mixed. The largest dataset is a 2018 Taiwanese national insurance cohort of 13,920 hormone therapy users. It recorded less tinnitus in that group, with an adjusted hazard ratio of 0.505. That study is old and observational, so it cannot establish cause. It is not a reason to use hormone therapy for tinnitus. Tinnitus that is unilateral, pulsatile, or associated with hearing loss requires ENT evaluation.
Itchy skin (pruritus) and dry skin
Estrogen supports dermal hydration, collagen content, and barrier function. Diffuse itch without rash is a recognized perimenopausal complaint.
Electric-shock sensations
Brief, jolt-like sensations often preceding a hot flash. Mechanism is poorly characterized but presumed to involve transient neuronal hyperexcitability during the lead-in to a vasomotor event.
Dry eyes in perimenopause
Estrogen and androgen receptors are present in lacrimal and meibomian glands; perimenopausal hormonal shifts reduce tear film stability.
Gum sensitivity, bleeding gums, burning mouth
Oral mucosa is estrogen-responsive. Burning mouth syndrome is more prevalent in perimenopausal and postmenopausal women, though it is not exclusive to this group.
Frozen shoulder (adhesive capsulitis)
Women aged 40 to 60 account for the majority of frozen shoulder cases. A 2025 narrative review describes adhesive capsulitis as an immunometabolic disorder. In it, estrogen-signaling failure weakens antifibrotic and anti-inflammatory defenses in joint capsule tissue. A Duke pilot study of 1,952 patients was published in Climacteric in January 2026. It found adhesive capsulitis in 3.95% of women on menopausal hormone therapy and 7.65% of women not on it. The odds ratio was 1.99, with a confidence interval of 0.86 to 4.58 and a p value of 0.10. That result is not statistically significant. So the study does not show that hormone therapy protects you from frozen shoulder.
Body odor change
Sweat composition shifts during the transition due to autonomic and skin-flora changes.
Brittle nails in perimenopause
Reduced collagen synthesis and slower keratin growth contribute to splitting and ridging.
The full 34-symptom inventory: mechanism, prevalence, and trackability
The table below consolidates the widely circulated "34 symptoms" with the best available mechanism and prevalence data. Where high-quality prevalence figures do not exist, the cell is marked limited data.
| # | Symptom | Primary hormonal driver | Estimated peri prevalence | Trackable at home |
|---|---|---|---|---|
| 1 | Hot flashes | Hypothalamic KNDy hyperactivity from estrogen withdrawal | ~43% (SWAN) | Y |
| 2 | Night sweats | Same as hot flashes, nocturnal expression | ~40–50% | Y |
| 3 | Irregular periods | Increased anovulatory cycles, FSH rise | ~70%+ | Y |
| 4 | Heavier periods | Unopposed estrogen → endometrial thickening | ~25% | Y (track flow / clots) |
| 5 | Insomnia / fragmented sleep | Loss of GABAergic progesterone metabolites; nocturnal VMS | ~40–60% | Y |
| 6 | Mood swings | Estrogen modulation of serotonin/dopamine | ~40–50% | Y |
| 7 | Anxiety | Reduced GABAergic tone (progesterone withdrawal) | ~30–40% | Y |
| 8 | Depressive symptoms | Estrogen and serotonin interaction; odds ratio 1.40 in perimenopause | ~20–30% | Y |
| 9 | Irritability | GABAergic withdrawal; sleep disruption | ~40% | Y |
| 10 | Brain fog / memory lapses | Estrogen support of hippocampal/PFC function | ~40–60% (SWAN) | Y |
| 11 | Difficulty concentrating | Same as brain fog | ~40% | Y |
| 12 | Fatigue | HPA-axis change; sleep disruption; possible thyroid | ~50%+ | Y |
| 13 | Low libido | Falling estrogen and testosterone; GSM | ~40–55% | Y |
| 14 | Vaginal dryness | Estrogen-dependent epithelial atrophy | 27–84% (GSM range) | Y |
| 15 | Painful intercourse | GSM, reduced lubrication and elasticity | ~30–45% | Y |
| 16 | Recurrent UTIs / urinary urgency | GSM-related urothelial change | ~20–35% | Y |
| 17 | Bladder leakage | Pelvic floor and urethral estrogen loss | ~30% | Y |
| 18 | Breast tenderness | Estrogen dominance relative to progesterone | ~25–40% | Y |
| 19 | Headaches / migraines | Estrogen withdrawal during luteal phase | ~30%; higher in migraine-history women | Y |
| 20 | Joint pain (arthralgia) | Estrogen–cartilage and IL-6 signaling | ~50–60% (SWAN) | Y |
| 21 | Muscle aches / loss of muscle mass | Estrogen and androgen effects on muscle protein synthesis | ~40%+ | Y |
| 22 | Frozen shoulder | Estrogen-signaling failure in joint capsule | ~2–5% population; female:male ~3:1 | N (clinical exam) |
| 23 | Weight gain (central) | Estrogen loss, cortisol, sleep disruption | ~60–70% | Y |
| 24 | Blood sugar swings | Reduced insulin sensitivity; cortisol | Limited cohort data | Y (CGM optional) |
| 25 | Palpitations | Autonomic / beta-adrenergic shifts | ~20–40% | Y (note triggers) |
| 26 | Dizziness / lightheadedness | Vasomotor and autonomic instability | ~20% | Y |
| 27 | Tinnitus | Cochlear vascular and neural estrogen effects | Limited data; ~10–20% report new tinnitus | Partial |
| 28 | Hair thinning / shedding | Shortened anagen phase; possible thyroid | ~30–50% | Y |
| 29 | Brittle nails | Reduced collagen and keratin turnover | Limited data | Y |
| 30 | Dry skin / itchy skin | Reduced dermal hydration and barrier function | ~30%+ | Y |
| 31 | Formication | Cutaneous nerve and dermal collagen changes | ~20% in some surveys | Y |
| 32 | Electric-shock sensations | Mechanism poorly characterized; precedes VMS | Limited data | Y |
| 33 | Burning mouth / gum issues | Estrogen-responsive oral mucosa | Limited data; ~5–15% | Partial (dentist exam) |
| 34 | Dry eyes | Lacrimal and meibomian gland estrogen/androgen receptors | ~20–30% | Y |
Estimated prevalence of the 34 symptoms during perimenopause
Prevalence estimates from the inventory table above, sorted from most to least common. Figures are estimates, as in the table. Where the source gives a range, the solid part of the bar reaches the lower figure and the lighter part carries the rest; a lighter part running to the right edge means the figure is a floor ("~50%+"). Not plotted because the table lists only limited data: blood sugar swings, brittle nails and electric-shock sensations. Tinnitus and burning mouth are plotted from the partial figures the table gives.
When to escalate: red-flag symptoms requiring urgent care
Not every perimenopausal symptom is benign. Some warrant same-day medical attention to exclude conditions that mimic the transition. The triage table below is conservative by design.
| Severity tier | Symptom or pattern | Action |
|---|---|---|
| Urgent, same day | Any vaginal bleeding 12 or more months after the last menstrual period | Postmenopausal bleeding requires same-day clinical evaluation to exclude endometrial cancer (per ACOG) |
| Urgent, same day | Chest pain, pressure, jaw or arm pain with shortness of breath | Call 911, cardiac evaluation required |
| Urgent, same day | Sudden severe headache, vision change, or one-sided weakness | Call 911, exclude stroke or other neurological emergency |
| Urgent, same day | Suicidal thoughts, plans, or active intent | Call or text 988 (Suicide and Crisis Lifeline) or go to the nearest emergency department |
| Urgent, same day | Pulsatile or unilateral tinnitus with hearing loss | ENT same-day or urgent referral |
| This week | Heavy menstrual bleeding (soaking through protection <2 hours, large clots, anemia symptoms) | Schedule with a gynecology provider this week |
| This week | New palpitations with syncope, dyspnea, or known heart disease | Cardiology referral and ECG |
| This week | New severe depression, anxiety preventing function | Behavioral health appointment within days |
| This month | Hot flashes, night sweats, mood lability, joint pain disrupting daily life | Track and discuss at next primary care or menopause-trained visit |
| Track at home | Mild VMS, occasional sleep disruption, mild brain fog, intermittent breast tenderness | Symptom diary; review at routine visit |
What functional medicine practitioners look for
Within functional medicine, a framework defined by the Institute for Functional Medicine, perimenopausal evaluation typically extends beyond confirming your menopausal stage. Practitioners commonly review your symptom clusters in the context of systems that interact with sex-hormone change: HPA-axis output, thyroid function, insulin and glucose regulation, gut health, micronutrient status, and inflammatory markers. The clinical reasoning is that two women with identical hormone levels can experience very different symptom severity depending on these adjacent systems.
A functional medicine intake for a perimenopausal patient often includes structured symptom inventories, a timeline of when each symptom appeared relative to your cycle changes, and a sleep-architecture history. Laboratory testing may extend to a complete thyroid panel (TSH, free T3, free T4, thyroid antibodies), fasting insulin and HbA1c, a 4-point salivary or 24-hour urinary cortisol, sex-hormone testing interpreted in the context of cycle phase, and inflammatory markers such as hs-CRP. Specific testing decisions are individualized. This article is descriptive, not prescriptive.
The 2017 re-analysis of the Women's Health Initiative reported a mortality reduction in women who started menopausal hormone therapy before age 60 or within 10 years of menopause onset. That narrowed the older blanket caution around hormone therapy. The labels themselves have since changed. On November 10, 2025 the FDA removed the boxed warnings from menopausal hormone therapy products. Updated labels for six products were approved on February 12, 2026. The new labeling recommends starting therapy within 10 years of menopause, or before age 60. The warning about endometrial cancer with estrogen-alone therapy was kept. This evidence shift means treatment conversations now happen earlier and with more nuance than in the previous decade. But they remain the domain of your treating clinician, not an article.
When to consider booking a consult
A deeper workup may be reasonable when several of the situations below are present.
- Three or more symptoms from the inventory above are present at moderate-to-severe intensity
- Sleep has been consistently disrupted for more than four weeks
- Cycle changes are accompanied by very heavy bleeding, prolonged bleeding, or new clotting
- Cognitive symptoms (word-finding, recall, concentration) are interfering with work
- New-onset anxiety or depression that does not respond to baseline lifestyle support
- Joint pain, frozen shoulder, or muscle loss is progressing despite activity
- Standard primary-care evaluation has "come back normal" but symptoms persist
- Family history of early menopause, cardiovascular disease, osteoporosis, or breast cancer is shaping risk decisions
A note for Texas. Two bills filed in March 2025 would have changed menopause care in the state. HB 3814 addressed insurance coverage, and HB 3961 proposed an education program run by the state health department. Both died in committee. So what your plan covers still depends on the plan itself, not on state law.
Booking a consultation with a clinician familiar with perimenopausal physiology is not a commitment to any specific treatment. It is an opportunity to get an individualized workup and a transparent discussion of the evidence behind each potential next step. A full overview of the transition is available in the complete perimenopause guide.
Frequently asked questions
Where did the "34 symptoms of perimenopause" list come from?
The list grew out of patient-advocacy and consumer-education materials in the early 2000s, particularly in the UK and US. They compiled the most frequently reported complaints during the menopausal transition. It is not a medical classification, and it is not endorsed by The Menopause Society or the Endocrine Society. Both organizations describe the transition through the STRAW+10 staging system and group symptoms by physiological domain. The "34" framework is useful as an awareness tool because it names experiences women often dismiss as unrelated. It should not be used as a diagnostic checklist.
Are all 34 symptoms caused by low estrogen?
No. Estrogen withdrawal and fluctuation drive many of the most prominent symptoms (hot flashes, vaginal dryness, joint pain, brain fog). But progesterone loss, HPA-axis change, thyroid status, and metabolic shifts all contribute. Anxiety and insomnia, for example, are tied more closely to falling progesterone and its GABAergic metabolite allopregnanolone than to estrogen. Weight gain and fatigue often reflect a combination of estrogen loss, cortisol-rhythm change, and sleep disruption. This is why the article maps each symptom to its dominant mechanism rather than attributing the entire list to one hormone.
How long do perimenopausal symptoms last?
The menopausal transition typically lasts four to eight years, but vasomotor symptoms can persist longer. SWAN data found a median total vasomotor symptom duration of approximately 7.4 years, with substantial variation by race, ethnicity, and age at onset. If your symptoms began before the final menstrual period, your total duration is likely to be longer. Genitourinary symptoms tend to persist or worsen postmenopause without intervention, because the underlying tissue change does not reverse. Vasomotor symptoms eventually subside in most women.
Which symptoms are most likely to be mistaken for something else?
Fatigue, brain fog, weight gain, hair thinning, cold intolerance, and mood change overlap substantially with hypothyroidism and depression. Joint pain and frozen shoulder are often first attributed to overuse or osteoarthritis. Palpitations may be attributed to anxiety when an arrhythmia or thyroid issue is present. This overlap is why a reasonable initial workup includes thyroid testing, basic metabolic and lipid panels, and a careful symptom history before attributing your complaints to perimenopause alone.
Is heavy bleeding in perimenopause normal?
Heavier-than-usual bleeding during perimenopause is common, because anovulatory cycles produce unopposed estrogen and endometrial thickening. However, certain patterns warrant evaluation: soaking through protection in under two hours, passing large clots, bleeding longer than seven days, bleeding between cycles, and any vaginal bleeding 12 months or more after your last period. That last one is postmenopausal bleeding. It requires same-day clinical evaluation to exclude endometrial cancer or hyperplasia, per ACOG guidance.
Can perimenopause cause symptoms before periods change?
Yes. The STRAW+10 framework describes a late reproductive stage (Stage −3) in which cycles remain regular but subtle hormonal changes are already under way, particularly altered FSH and inhibin B. Those changes can already produce sleep, mood, and cognitive symptoms. Many women describe "feeling off" for one to three years before any cycle irregularity. This is one reason it can take time to get a perimenopause diagnosis. It is also why a clinician familiar with the transition will weigh your symptom pattern rather than relying solely on cycle history or a single hormone measurement.
References
- Harlow SD, et al. Journal of Clinical Endocrinology and Metabolism. 2012. https://pubmed.ncbi.nlm.nih.gov/22344196/
- Aras SG, et al. Scientific Reports. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11699220/
- The Menopause Society. The Menopause Society. 2026. https://menopause.org/press-releases/international-differences-exist-in-knowledge-gaps-and-most-common-perimenopause-symptoms
- Mittelman-Smith MA, et al. Proceedings of the National Academy of Sciences. 2012. https://www.pnas.org/doi/10.1073/pnas.1211517109
- Michael E, et al. Healio. 2025. https://www.healio.com/news/womens-health-ob-gyn/20251024/fda-approves-lynkuet-for-moderate-to-severe-hot-flashes-due-to-menopause
- The North American Menopause Society. Menopause. 2020. https://pubmed.ncbi.nlm.nih.gov/32852449/
- American Urological Association, SUFU and AUGS. American Urological Association. 2025. https://www.auanet.org/guidelines-and-quality/guidelines/genitourinary-syndrome-of-menopause
- Wright VJ, et al. Climacteric. 2024. https://pubmed.ncbi.nlm.nih.gov/39077777/
- Gangwar V, et al. Journal of Mid-life Health. 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC13160532/
- Greendale GA, et al. American Journal of Epidemiology. 2010. https://pmc.ncbi.nlm.nih.gov/articles/PMC2915492/
- Chen HC, et al. Oncotarget. 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC5929427/
- Navarro-Ledesma S. Journal of Clinical Medicine. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12564958/
- Manson JE, et al. JAMA. 2017. https://pubmed.ncbi.nlm.nih.gov/28898378/
- U.S. Food and Drug Administration. U.S. Food and Drug Administration. 2025. https://www.fda.gov/news-events/press-announcements/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy
- U.S. Food and Drug Administration. U.S. Food and Drug Administration. 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
About the author
Anna Evans MSN, APRN, FNP-C
Founder, Interlinked Wellness
Anna Evans, MSN, APRN, FNP-C is a board-certified Family Nurse Practitioner licensed in Texas. She founded Interlinked Wellness, a virtual functional medicine practice serving women across Texas from offices in Dallas and Austin. Her clinical focus is perimenopause, hormone imbalance, gut health, thyroid and autoimmune conditions, and chronic fatigue.
More about Anna · Schedule a consultation · LinkedIn · Instagram
Medical disclaimer. The information on this page is provided for general education and is not individualized medical advice. At Interlinked Wellness, Anna Evans, MSN, APRN, FNP-C, provides personalized care based on your health history, symptoms, concerns, and goals. An individual consultation allows Anna to evaluate your specific situation and recommend an appropriate approach to care. Reading this page alone does not establish a patient-provider relationship. If you are experiencing a medical emergency, call 911 or your local emergency services.
Join Anna on a virtual wellness journey and unlock your full potential.
